Home Colorectal Cancer Global Oncology Molecular Diagnostics Industry

Global Oncology Molecular Diagnostics Industry

48
0

New York, Sept. 29, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Oncology Molecular Diagnostics Industry” – https://www.reportlinker.com/p05957565/?utm_source=GNW
6 Billion by 2027, growing at a CAGR of 11.2% over the analysis period 2020-2027.Breast Cancer, one of the segments analyzed in the report, is projected to grow at a 8.7% CAGR to reach US$900.3 Million by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Colorectal Cancer segment is readjusted to a revised 14.5% CAGR for the next 7-year period. This segment currently accounts for a 25.8% share of the global Oncology Molecular Diagnostics market.

The U.S. Accounts for Over 28.8% of Global Market Size in 2020, While China is Forecast to Grow at a 14.9% CAGR for the Period of 2020-2027

The Oncology Molecular Diagnostics market in the U.S. is estimated at US$490.5 Million in the year 2020. The country currently accounts for a 28.84% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$669.6 Million in the year 2027 trailing a CAGR of 14.9% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.9% and 9.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.8% CAGR while Rest of European market (as defined in the study) will reach US$669.6 Million by the year 2027.

Prostate Cancer Segment Corners a 18.2% Share in 2020

In the global Prostate Cancer segment, USA, Canada, Japan, China and Europe will drive the 11.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$233.6 Million in the year 2020 will reach a projected size of US$506.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$533.5 Million by the year 2027, while Latin America will expand at a 14% CAGR through the analysis period. We bring years of research experience to this 7th edition of our report. The 287-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • Abbott Laboratories
  • Bayer Healthcare AG
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Cepheid, Inc.
  • Danaher Corporation
  • Hologic, Inc.
  • Leica Biosystems Inc.
  • Qiagen NV
  • Roche Diagnostics (Schweiz) AG
  • Siemens Healthineers
  • Sysmex Corporation

Read the full report: https://www.reportlinker.com/p05957565/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
Global Competitor Market Shares
Oncology Molecular Diagnostics Competitor Market Share Scenario
Worldwide (in %): 2018E

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Oncology Molecular
Diagnostics by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2018 through 2027

Table 2: World Historic Review for Oncology Molecular
Diagnostics by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 3: World 15-Year Perspective for Oncology Molecular
Diagnostics by Geographic Region – Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2018 & 2027

Table 4: World Current & Future Analysis for Breast Cancer by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 5: World Historic Review for Breast Cancer by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 6: World 15-Year Perspective for Breast Cancer by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 7: World Current & Future Analysis for Colorectal Cancer
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 8: World Historic Review for Colorectal Cancer by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 9: World 15-Year Perspective for Colorectal Cancer by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 10: World Current & Future Analysis for Prostate Cancer
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 11: World Historic Review for Prostate Cancer by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 12: World 15-Year Perspective for Prostate Cancer by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 13: World Current & Future Analysis for Cervical Cancer
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 14: World Historic Review for Cervical Cancer by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 15: World 15-Year Perspective for Cervical Cancer by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 16: World Current & Future Analysis for Other Disease
Types by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 17: World Historic Review for Other Disease Types by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 18: World 15-Year Perspective for Other Disease Types by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 19: World Current & Future Analysis for Instruments by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 20: World Historic Review for Instruments by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 21: World 15-Year Perspective for Instruments by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 22: World Current & Future Analysis for Reagents by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 23: World Historic Review for Reagents by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 24: World 15-Year Perspective for Reagents by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2018 & 2027

Table 25: World Current & Future Analysis for Other Segments by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 26: World Historic Review for Other Segments by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 27: World 15-Year Perspective for Other Segments by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US Oncology Molecular Diagnostics Market Share (in %) by
Company: 2018 & 2027
Market Analytics
Table 28: USA Current & Future Analysis for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types –
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 29: USA Historic Review for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 30: USA 15-Year Perspective for Oncology Molecular
Diagnostics by Disease Type – Percentage Breakdown of Value
Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer,
Cervical Cancer and Other Disease Types for the Years 2012,
2018 & 2027

Table 31: USA Current & Future Analysis for Oncology Molecular
Diagnostics by Segment – Instruments, Reagents and Other
Segments – Independent Analysis of Annual Sales in US$ Billion
for the Years 2018 through 2027

Table 32: USA Historic Review for Oncology Molecular
Diagnostics by Segment – Instruments, Reagents and Other
Segments Markets – Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 33: USA 15-Year Perspective for Oncology Molecular
Diagnostics by Segment – Percentage Breakdown of Value Sales
for Instruments, Reagents and Other Segments for the Years
2012, 2018 & 2027

CANADA
Table 34: Canada Current & Future Analysis for Oncology
Molecular Diagnostics by Disease Type – Breast Cancer,
Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other
Disease Types – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 35: Canada Historic Review for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 36: Canada 15-Year Perspective for Oncology Molecular
Diagnostics by Disease Type – Percentage Breakdown of Value
Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer,
Cervical Cancer and Other Disease Types for the Years 2012,
2018 & 2027

Table 37: Canada Current & Future Analysis for Oncology
Molecular Diagnostics by Segment – Instruments, Reagents and
Other Segments – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 38: Canada Historic Review for Oncology Molecular
Diagnostics by Segment – Instruments, Reagents and Other
Segments Markets – Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 39: Canada 15-Year Perspective for Oncology Molecular
Diagnostics by Segment – Percentage Breakdown of Value Sales
for Instruments, Reagents and Other Segments for the Years
2012, 2018 & 2027

JAPAN
Table 40: Japan Current & Future Analysis for Oncology
Molecular Diagnostics by Disease Type – Breast Cancer,
Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other
Disease Types – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 41: Japan Historic Review for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 42: Japan 15-Year Perspective for Oncology Molecular
Diagnostics by Disease Type – Percentage Breakdown of Value
Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer,
Cervical Cancer and Other Disease Types for the Years 2012,
2018 & 2027

Table 43: Japan Current & Future Analysis for Oncology
Molecular Diagnostics by Segment – Instruments, Reagents and
Other Segments – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 44: Japan Historic Review for Oncology Molecular
Diagnostics by Segment – Instruments, Reagents and Other
Segments Markets – Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 45: Japan 15-Year Perspective for Oncology Molecular
Diagnostics by Segment – Percentage Breakdown of Value Sales
for Instruments, Reagents and Other Segments for the Years
2012, 2018 & 2027

CHINA
Table 46: China Current & Future Analysis for Oncology
Molecular Diagnostics by Disease Type – Breast Cancer,
Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other
Disease Types – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 47: China Historic Review for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 48: China 15-Year Perspective for Oncology Molecular
Diagnostics by Disease Type – Percentage Breakdown of Value
Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer,
Cervical Cancer and Other Disease Types for the Years 2012,
2018 & 2027

Table 49: China Current & Future Analysis for Oncology
Molecular Diagnostics by Segment – Instruments, Reagents and
Other Segments – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 50: China Historic Review for Oncology Molecular
Diagnostics by Segment – Instruments, Reagents and Other
Segments Markets – Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 51: China 15-Year Perspective for Oncology Molecular
Diagnostics by Segment – Percentage Breakdown of Value Sales
for Instruments, Reagents and Other Segments for the Years
2012, 2018 & 2027

EUROPE
Market Facts & Figures
European Oncology Molecular Diagnostics Market: Competitor
Market Share Scenario (in %) for 2018 & 2027
Market Analytics
Table 52: Europe Current & Future Analysis for Oncology
Molecular Diagnostics by Geographic Region – France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 53: Europe Historic Review for Oncology Molecular
Diagnostics by Geographic Region – France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets – Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 54: Europe 15-Year Perspective for Oncology Molecular
Diagnostics by Geographic Region – Percentage Breakdown of
Value Sales for France, Germany, Italy, UK, Spain, Russia and
Rest of Europe Markets for Years 2012, 2018 & 2027

Table 55: Europe Current & Future Analysis for Oncology
Molecular Diagnostics by Disease Type – Breast Cancer,
Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other
Disease Types – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 56: Europe Historic Review for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 57: Europe 15-Year Perspective for Oncology Molecular
Diagnostics by Disease Type – Percentage Breakdown of Value
Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer,
Cervical Cancer and Other Disease Types for the Years 2012,
2018 & 2027

Table 58: Europe Current & Future Analysis for Oncology
Molecular Diagnostics by Segment – Instruments, Reagents and
Other Segments – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 59: Europe Historic Review for Oncology Molecular
Diagnostics by Segment – Instruments, Reagents and Other
Segments Markets – Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 60: Europe 15-Year Perspective for Oncology Molecular
Diagnostics by Segment – Percentage Breakdown of Value Sales
for Instruments, Reagents and Other Segments for the Years
2012, 2018 & 2027

FRANCE
Table 61: France Current & Future Analysis for Oncology
Molecular Diagnostics by Disease Type – Breast Cancer,
Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other
Disease Types – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 62: France Historic Review for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 63: France 15-Year Perspective for Oncology Molecular
Diagnostics by Disease Type – Percentage Breakdown of Value
Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer,
Cervical Cancer and Other Disease Types for the Years 2012,
2018 & 2027

Table 64: France Current & Future Analysis for Oncology
Molecular Diagnostics by Segment – Instruments, Reagents and
Other Segments – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 65: France Historic Review for Oncology Molecular
Diagnostics by Segment – Instruments, Reagents and Other
Segments Markets – Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 66: France 15-Year Perspective for Oncology Molecular
Diagnostics by Segment – Percentage Breakdown of Value Sales
for Instruments, Reagents and Other Segments for the Years
2012, 2018 & 2027

GERMANY
Table 67: Germany Current & Future Analysis for Oncology
Molecular Diagnostics by Disease Type – Breast Cancer,
Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other
Disease Types – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 68: Germany Historic Review for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 69: Germany 15-Year Perspective for Oncology Molecular
Diagnostics by Disease Type – Percentage Breakdown of Value
Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer,
Cervical Cancer and Other Disease Types for the Years 2012,
2018 & 2027

Table 70: Germany Current & Future Analysis for Oncology
Molecular Diagnostics by Segment – Instruments, Reagents and
Other Segments – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 71: Germany Historic Review for Oncology Molecular
Diagnostics by Segment – Instruments, Reagents and Other
Segments Markets – Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 72: Germany 15-Year Perspective for Oncology Molecular
Diagnostics by Segment – Percentage Breakdown of Value Sales
for Instruments, Reagents and Other Segments for the Years
2012, 2018 & 2027

ITALY
Table 73: Italy Current & Future Analysis for Oncology
Molecular Diagnostics by Disease Type – Breast Cancer,
Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other
Disease Types – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 74: Italy Historic Review for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 75: Italy 15-Year Perspective for Oncology Molecular
Diagnostics by Disease Type – Percentage Breakdown of Value
Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer,
Cervical Cancer and Other Disease Types for the Years 2012,
2018 & 2027

Table 76: Italy Current & Future Analysis for Oncology
Molecular Diagnostics by Segment – Instruments, Reagents and
Other Segments – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 77: Italy Historic Review for Oncology Molecular
Diagnostics by Segment – Instruments, Reagents and Other
Segments Markets – Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 78: Italy 15-Year Perspective for Oncology Molecular
Diagnostics by Segment – Percentage Breakdown of Value Sales
for Instruments, Reagents and Other Segments for the Years
2012, 2018 & 2027

UNITED KINGDOM
Table 79: UK Current & Future Analysis for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types –
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 80: UK Historic Review for Oncology Molecular Diagnostics
by Disease Type – Breast Cancer, Colorectal Cancer, Prostate
Cancer, Cervical Cancer and Other Disease Types Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 81: UK 15-Year Perspective for Oncology Molecular
Diagnostics by Disease Type – Percentage Breakdown of Value
Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer,
Cervical Cancer and Other Disease Types for the Years 2012,
2018 & 2027

Table 82: UK Current & Future Analysis for Oncology Molecular
Diagnostics by Segment – Instruments, Reagents and Other
Segments – Independent Analysis of Annual Sales in US$ Billion
for the Years 2018 through 2027

Table 83: UK Historic Review for Oncology Molecular Diagnostics
by Segment – Instruments, Reagents and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 84: UK 15-Year Perspective for Oncology Molecular
Diagnostics by Segment – Percentage Breakdown of Value Sales
for Instruments, Reagents and Other Segments for the Years
2012, 2018 & 2027

SPAIN
Table 85: Spain Current & Future Analysis for Oncology
Molecular Diagnostics by Disease Type – Breast Cancer,
Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other
Disease Types – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 86: Spain Historic Review for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 87: Spain 15-Year Perspective for Oncology Molecular
Diagnostics by Disease Type – Percentage Breakdown of Value
Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer,
Cervical Cancer and Other Disease Types for the Years 2012,
2018 & 2027

Table 88: Spain Current & Future Analysis for Oncology
Molecular Diagnostics by Segment – Instruments, Reagents and
Other Segments – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 89: Spain Historic Review for Oncology Molecular
Diagnostics by Segment – Instruments, Reagents and Other
Segments Markets – Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 90: Spain 15-Year Perspective for Oncology Molecular
Diagnostics by Segment – Percentage Breakdown of Value Sales
for Instruments, Reagents and Other Segments for the Years
2012, 2018 & 2027

RUSSIA
Table 91: Russia Current & Future Analysis for Oncology
Molecular Diagnostics by Disease Type – Breast Cancer,
Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other
Disease Types – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 92: Russia Historic Review for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 93: Russia 15-Year Perspective for Oncology Molecular
Diagnostics by Disease Type – Percentage Breakdown of Value
Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer,
Cervical Cancer and Other Disease Types for the Years 2012,
2018 & 2027

Table 94: Russia Current & Future Analysis for Oncology
Molecular Diagnostics by Segment – Instruments, Reagents and
Other Segments – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 95: Russia Historic Review for Oncology Molecular
Diagnostics by Segment – Instruments, Reagents and Other
Segments Markets – Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 96: Russia 15-Year Perspective for Oncology Molecular
Diagnostics by Segment – Percentage Breakdown of Value Sales
for Instruments, Reagents and Other Segments for the Years
2012, 2018 & 2027

REST OF EUROPE
Table 97: Rest of Europe Current & Future Analysis for Oncology
Molecular Diagnostics by Disease Type – Breast Cancer,
Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other
Disease Types – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 98: Rest of Europe Historic Review for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 99: Rest of Europe 15-Year Perspective for Oncology
Molecular Diagnostics by Disease Type – Percentage Breakdown of
Value Sales for Breast Cancer, Colorectal Cancer, Prostate
Cancer, Cervical Cancer and Other Disease Types for the Years
2012, 2018 & 2027

Table 100: Rest of Europe Current & Future Analysis for
Oncology Molecular Diagnostics by Segment – Instruments,
Reagents and Other Segments – Independent Analysis of Annual
Sales in US$ Billion for the Years 2018 through 2027

Table 101: Rest of Europe Historic Review for Oncology
Molecular Diagnostics by Segment – Instruments, Reagents and
Other Segments Markets – Independent Analysis of Annual Sales
in US$ Billion for Years 2012 through 2017

Table 102: Rest of Europe 15-Year Perspective for Oncology
Molecular Diagnostics by Segment – Percentage Breakdown of
Value Sales for Instruments, Reagents and Other Segments for
the Years 2012, 2018 & 2027

ASIA-PACIFIC
Table 103: Asia-Pacific Current & Future Analysis for Oncology
Molecular Diagnostics by Geographic Region – Australia, India,
South Korea and Rest of Asia-Pacific Markets – Independent
Analysis of Annual Sales in US$ Billion for Years 2018 through
2027

Table 104: Asia-Pacific Historic Review for Oncology Molecular
Diagnostics by Geographic Region – Australia, India, South
Korea and Rest of Asia-Pacific Markets – Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 105: Asia-Pacific 15-Year Perspective for Oncology
Molecular Diagnostics by Geographic Region – Percentage
Breakdown of Value Sales for Australia, India, South Korea and
Rest of Asia-Pacific Markets for Years 2012, 2018 & 2027

Table 106: Asia-Pacific Current & Future Analysis for Oncology
Molecular Diagnostics by Disease Type – Breast Cancer,
Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other
Disease Types – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 107: Asia-Pacific Historic Review for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 108: Asia-Pacific 15-Year Perspective for Oncology
Molecular Diagnostics by Disease Type – Percentage Breakdown of
Value Sales for Breast Cancer, Colorectal Cancer, Prostate
Cancer, Cervical Cancer and Other Disease Types for the Years
2012, 2018 & 2027

Table 109: Asia-Pacific Current & Future Analysis for Oncology
Molecular Diagnostics by Segment – Instruments, Reagents and
Other Segments – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 110: Asia-Pacific Historic Review for Oncology Molecular
Diagnostics by Segment – Instruments, Reagents and Other
Segments Markets – Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 111: Asia-Pacific 15-Year Perspective for Oncology
Molecular Diagnostics by Segment – Percentage Breakdown of
Value Sales for Instruments, Reagents and Other Segments for
the Years 2012, 2018 & 2027

AUSTRALIA
Table 112: Australia Current & Future Analysis for Oncology
Molecular Diagnostics by Disease Type – Breast Cancer,
Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other
Disease Types – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 113: Australia Historic Review for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 114: Australia 15-Year Perspective for Oncology Molecular
Diagnostics by Disease Type – Percentage Breakdown of Value
Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer,
Cervical Cancer and Other Disease Types for the Years 2012,
2018 & 2027

Table 115: Australia Current & Future Analysis for Oncology
Molecular Diagnostics by Segment – Instruments, Reagents and
Other Segments – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 116: Australia Historic Review for Oncology Molecular
Diagnostics by Segment – Instruments, Reagents and Other
Segments Markets – Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 117: Australia 15-Year Perspective for Oncology Molecular
Diagnostics by Segment – Percentage Breakdown of Value Sales
for Instruments, Reagents and Other Segments for the Years
2012, 2018 & 2027

INDIA
Table 118: India Current & Future Analysis for Oncology
Molecular Diagnostics by Disease Type – Breast Cancer,
Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other
Disease Types – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 119: India Historic Review for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 120: India 15-Year Perspective for Oncology Molecular
Diagnostics by Disease Type – Percentage Breakdown of Value
Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer,
Cervical Cancer and Other Disease Types for the Years 2012,
2018 & 2027

Table 121: India Current & Future Analysis for Oncology
Molecular Diagnostics by Segment – Instruments, Reagents and
Other Segments – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 122: India Historic Review for Oncology Molecular
Diagnostics by Segment – Instruments, Reagents and Other
Segments Markets – Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 123: India 15-Year Perspective for Oncology Molecular
Diagnostics by Segment – Percentage Breakdown of Value Sales
for Instruments, Reagents and Other Segments for the Years
2012, 2018 & 2027

SOUTH KOREA
Table 124: South Korea Current & Future Analysis for Oncology
Molecular Diagnostics by Disease Type – Breast Cancer,
Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other
Disease Types – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 125: South Korea Historic Review for Oncology Molecular
Diagnostics by Disease Type – Breast Cancer, Colorectal Cancer,
Prostate Cancer, Cervical Cancer and Other Disease Types
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 126: South Korea 15-Year Perspective for Oncology
Molecular Diagnostics by Disease Type – Percentage Breakdown of
Value Sales for Breast Cancer, Colorectal Cancer, Prostate
Cancer, Cervical Cancer and Other Disease Types for the Years
2012, 2018 & 2027

Table 127: South Korea Current & Future Analysis for Oncology
Molecular Diagnostics by Segment – Instruments, Reagents and
Other Segments – Independent Analysis of Annual Sales in US$
Billion for the Years 2018 through 2027

Table 128: South Korea Historic Review for Oncology Molecular

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05957565/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

https://www.globenewswire.com/news-release/2020/09/29/2100265/0/en/Global-Oncology-Molecular-Diagnostics-Industry.html

This site uses Akismet to reduce spam. Learn how your comment data is processed.